Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2019; 25(13): 1592-1602
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1592
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1592
Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding
Francesco Vitali, Andreas Naegel, Raja Atreya, Steffen Zopf, Clemens Neufert, Juergen Siebler, Markus F Neurath, Timo Rath, Ludwig Demling Endoscopy Center of Excellence, Division of Gastroenterology, Friedrich-Alexander-University, Erlangen 91054, Germany
Author contributions: Rath T designed the study; Vitali F, Naegel A, Atreya R, Neufert C and Rath T participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript; Vitali F wrote the article; Siebler J and Neurath MF revised the article critically for important intellectual content.
Institutional review board statement: The study was reviewed and approved by ethical committee of the Friedrich-Alexander-University Erlangen- Nuernberg, Germany. The scanned copy of ethical committee approval of the research protocol was attached in submitted files to the journal.
Informed consent statement: As retrospective cohort study informed patients’ consent was waived from the ethic committee
Conflict-of-interest statement: There are no conflicts of interest to report.
STROBE statement: The authors have read the STROBE Statement- checklist of items and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Timo Rath, MD, PhD, Full Professor, Ludwig Demling Endoscopy Center of Excellence, Division of Gastroenterology, Friedrich-Alexander-University, FAU Erlangen-Nuremberg, Ulmenweg 18, Erlangen 91054, Germany. timo.rath@uk-erlangen.de
Telephone: +49-9131-8535000 Fax: +49-9131-8535252
Received: December 22, 2018
Peer-review started: December 25, 2018
First decision: February 21, 2019
Revised: March 6, 2019
Accepted: March 11, 2019
Article in press: March 12, 2019
Published online: April 7, 2019
Processing time: 103 Days and 4.7 Hours
Peer-review started: December 25, 2018
First decision: February 21, 2019
Revised: March 6, 2019
Accepted: March 11, 2019
Article in press: March 12, 2019
Published online: April 7, 2019
Processing time: 103 Days and 4.7 Hours
Core Tip
Core tip: Hemostatic powders represent “touch-free” hemostatic agents for the treatment of gastrointestinal bleeding. Within this study, we analyzed the hemostatic efficacy of hemostatic powders as first line or salvage therapy in several clinical scenarios in a large cohort of prospectively included patients. As shown in our report, both hemostatic powders allow for excellent short term bleeding control while at the same time, long term efficacy over a period of 4 wk is maintained in a considerable amount of patients. No differences were observed between Hemospray and Endoclot in their hemostatic efficacy.